# SymBio Pharmaceuticals

Source: https://onco.cc/companies/symbio-pharmaceuticals/  
OnCo record `symbio-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SymBio is a Tokyo company that brought bendamustine (Treakisym) to Japan for lymphoma and myeloma through the local trials it led, and now develops the antiviral brincidofovir for transplant complications.

## Summary

SymBio Pharmaceuticals, founded in 2005 in Minato, Tokyo, in-licenses medicines for Japan and runs the domestic trials for approval. It won Japanese approval for bendamustine (Treakisym) in relapsed indolent lymphoma, mantle cell lymphoma and later first-line settings, and is developing brincidofovir for adenovirus infection after stem cell transplant. Its phase 3 trials are registered on ClinicalTrials.gov under SymBio as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: SymBio Pharmaceuticals Limited; シンバイオ製薬
- Tags: ctgov-sponsor
- HQ: Tokyo
- Type: pharma
- Website: http://www.symbiopharma.com

## Sources

- Official website: http://www.symbiopharma.com
- ClinicalTrials.gov: trials led by SymBio Pharmaceuticals Limited: https://clinicaltrials.gov/search?lead=SymBio%20Pharmaceuticals%20Limited
- Wikidata: https://www.wikidata.org/wiki/Q38277748

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/symbio-pharmaceuticals.json